- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02056847
to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia (SIPHON)
Randomized, Open-label, Multi-centered Study to Evaluate the Safety and Efficacy of Pitavastatin in Patients With Impaired Fasting Glucose and Hyperlipidemia(Phase 4)
Primary Objective
: To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting glucose (IFG).
H0: µT-µC ≥ 0.4 vs H1: µT-µC < 0.4
µT = the change of HbA1c in the test drug (Pitavastatin 4 MG) µC = the change of HbA1c in the control drug (Pitavastatin 2 MG)
Study Overview
Status
Intervention / Treatment
Detailed Description
Investigational Product Test group: Pitavastatin calcium (LIVALO) 4mg tab Control group: Pitavastatin calcium (LIVALO) 2mg tab
Study Site: Multi-centers in Korea
Period: For 24months after IRB approval at each site (Including 12months of subject enrollment period)
Efficacy End points
A. Primary end point The change of HbA1c before and after taking LIVALO
B. Secondary end point
- Incidence of diabetes within 1year after registration (based; FPG ≥126mg/dL or to need taking diabetes medication)
- Incidence of major cardiovascular (TLR-MACE) events within 1 year after registration
- Incidence of total cardiovascular (TVR-MACE) events within 1 year after registration
- The change of the lipid composition (T-chol, TG, LDL-C, HDL-C, ApoA1/ApoB)
- The changes of hs-CRP
- The changes of Adiponectin
- The change of blood glucose and Insulin levels FPG(Fasting Plasma Glucose) Fasting Serum Insulin HOMA IR [fasting insulin(µIU/mL) X fasting glucose(mg/dL)]/405 HOMA β [360 X fasting insulin(µIU/mL)]/[fasting glucose(mg/dL)-63]
Statistical Methods
Efficacy A. Primary efficacy endpoint analysis Describe statistics of basic about the HbA1c variation before and after taking LIVALO by groups. In order to verify noninferiority of test drug, check that upper limit of confidence interval of the one-sided 97.5% is less than 0.4% about difference of HbA1c variation between the control group and the test group, before and after taking LIVALO.
B. Secondary efficacy endpoint analysis Continuous variables
:Present the mean, standard deviation, minimum, and maximum values for TC, TG, LDL-C, HDL-C, Fasting serum insulin, Fasting plasma glucose and HOMA IR, HOMA β etc. by each visit and in each group. In comparison with intergroup, using two-sample t-test for normal distribution and using Wilcoxon rank sum test for non-normal distribution. Also In comparison with the same group, using paired t-test for normal distribution and using Wilcoxon signed rank test for non-normal distribution.
Discrete variables
: The number and percentage of the subjects for incidence of DM and cardiovascular event are described of each group and the ratio of the intergroup comparison use χ2-test or Fisher's exact test.
- Safety All the AEs and the ADRs which manifested more than once are described by the frequency and percentage of each group and use χ2-test or Fisher's exact test for intergroup comparison about the rate of AEs and ADRs Laboratory tests and vital signs are analyzed descriptive statistics quantity of each group, and in comparison with intergroup, use two-sample t-test for normal distribution and use Wilcoxon rank sum test for non-normal distribution. Also, In comparison with the same group, use paired t-test for normal distribution and use Wilcoxon signed rank test for non-normal distribution.
Clinical laboratory test is analyzed the frequency and percentage of the outside normal range of subjects, and using χ2-test or Fisher's exact test with intergroup.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 137-864
- JW Pharmaceutical
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and Female patients who are more than 20 years old or 70 years old or less.
- Patient who voluntarily sign on written informed consent form
- Patient who LDL-C ≥ 100mg/dl or was diagnosed with hyperlipidemia
- Patient who was suspected with Imparied Fasting Glucose (IFG) and satisfy FPG level ≥ 100mg/dL and < 126mg/dL when FPG measured twice.
Exclusion Criteria:
- Patient who has familial hypercholesterolemia
- Patient who has been diagnosed with Type1, Type2 DM or secondary DM(diabetes mellitus) at the screening visit (Diagnostic criteria of DM: HbA1c≥ 6.5%)
- Patient who has received antidiabetic within 6weeks to the screening visit
- Patient who has been taking insulin continuously or to be needed in the future
- Patient who has a history of gastrectomy
- Patient who is suspected or diagnosed with malignant tumor within last 10 years
- Patient who has serious pancreatic disease or endocrine disorders
- Patient who currently takes Cyclosporine
- Patient who has a medical history of hypersensitivity to Pitavastatin calcium
- Patient who has suspected renal failure (serum creatinine ≥2.0 mg/dL)
- Patient who has suspected liver dysfunction (more than 2.5 times the upper limit of normal AST or ALT)
- Patient who has more than 3 times the upper limit of normal CPK
- Patient who is breastfeeding, pregnant or planning pregnancy
- Patient who deemed inappropriate as subject in the opinion of the Principal Investigator or Investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Pitavastatin calcium 4mg
Pitavastatin calcium (LIVALO®) 4mg, once a day
|
taking once a day
Other Names:
|
Active Comparator: Pitavastatin calcium 2mg
Pitavastatin calcium (LIVALO®) 2mg, once a day
|
Taking once a day
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The change of HbA1c before and after taking LIVALO®
Time Frame: 24 weeks after taking IP
|
24 weeks after taking IP
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of diabetes
Time Frame: within 1year after registration
|
based; FPG ≥126mg/dL or to need taking diabetes medication
|
within 1year after registration
|
Incidence of total cardiovascular (TVR-MACE) events
Time Frame: within 1 year after registration
|
within 1 year after registration
|
|
The change of the lipid composition (T-chol, TG, LDL-C, HDL-C, ApoA1/ApoB)
Time Frame: 24weeks and 1 year after registration
|
24weeks and 1 year after registration
|
|
The changes of hs-CRP, Adiponectin, blood glucose and Insulin levels
Time Frame: 24weeks and 1 year after registration
|
The change of blood glucose and Insulin levels FPG(Fasting Plasma Glucose) Fasting Serum Insulin HOMA IR [fasting insulin(µIU/mL) X fasting glucose(mg/dL)]/405 HOMA β [360 X fasting insulin(µIU/mL)]/[fasting glucose(mg/dL)-63]
|
24weeks and 1 year after registration
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: NamSik Chung, M.D., Ph D., Severance Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Lipid Metabolism Disorders
- Dyslipidemias
- Hyperlipidemias
- Hyperlipoproteinemias
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antimetabolites
- Anticholesteremic Agents
- Hypolipidemic Agents
- Lipid Regulating Agents
- Hydroxymethylglutaryl-CoA Reductase Inhibitors
- Bone Density Conservation Agents
- Calcium-Regulating Hormones and Agents
- Calcium
- Calcium, Dietary
- Pitavastatin
Other Study ID Numbers
- JW-PTV-713
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HbA1c Level Associated With Lipid Compositions
-
Taipei Veterans General Hospital, TaiwanUnknownDyslipidemia | Disorder Associated With Menstruation and/or MenopauseTaiwan
-
Ikaria Bioscience Pty LtdRecruitingTo Reduce the LDL-C Level in Hypercholesteremia Adult Patients | Combination for Subgroup High LDL-c Patients With Other ComorbiditiesAustralia
-
Capital Medical UniversityCompletedMechanical Ventilation Complication | Disorder; Mental, Sedative | Depressed Level of Consciousness | Psychosis Associated With Intensive CareChina
-
Capital Medical UniversityBeijing Municipal Health BureauCompletedMechanical Ventilation Complication | Disorder; Mental, Sedative | Depressed Level of Consciousness | Psychosis Associated With Intensive CareChina
-
Laboratorios Silanes S.A. de C.V.RecruitingDyslipidemia Associated With Type II Diabetes MellitusMexico
-
Assiut UniversityNot yet recruitingDyslipidemia Associated With Type II Diabetes Mellitus
-
EMSRecruitingDyslipidemia Associated With Type II Diabetes MellitusBrazil
-
Inova Health Care ServicesTerminatedDiabetes Mellitus, Type 2 | Percutaneous Coronary Intervention | Dyslipidemia Associated With Type II Diabetes MellitusUnited States
-
Daiichi Sankyo, Inc.Daiichi Sankyo Korea Co., Ltd.CompletedDyslipidemia Associated With Type II Diabetes MellitusKorea, Republic of
-
Damanhour UniversityTanta UniversityCompletedDyslipidemia Associated With Type II Diabetes MellitusEgypt
Clinical Trials on Pitavastatin calcium 4mg
-
Korea University Anam HospitalCompletedAtherosclerosis | Neointima | AnginaKorea, Republic of
-
Kowa Research Institute, Inc.CompletedSevere Renal ImpairmentUnited States
-
Kowa Research Institute, Inc.Completed
-
C.DirvenRecruitingRecurrent Glioblastoma | Glioblastoma Multiforme, AdultNetherlands
-
Philip Morris Products S.A.Active, not recruiting
-
JW PharmaceuticalRecruitingHypercholesterolemiaKorea, Republic of
-
Jun TaoSun Yat-sen UniversityUnknownHypertension | Dyslipidemias | Prediabetic StateChina
-
Hospital Israelita Albert EinsteinNovartis; epHealthCompletedMyocardial Infarction | Cardiovascular Diseases | Stroke | Hypertension | Diabetes Mellitus | DyslipidemiasBrazil
-
Shaochun.LiBeijing Friendship Hospital; Peking University Third Hospital; Xuanwu Hospital... and other collaboratorsUnknownDyslipidemia | Subclinical hypothyroïdism | ASCVD | StatinChina
-
Bio-Thera SolutionsCompletedWet Age-related Macular DegenerationChina